Washington, D.C. 20549




Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934


For the Month of April 2023



(Commission File Number)



(Exact name of Registrant as specified in its charter)


85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.


Form 20-F ☒ Form 40-F ☐






Exhibit Index




99.1   Press Release dated April 25, 2023






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


  Intercure Ltd.
Date: April 25, 2023 By: /s/ Amos Cohen
    Amos Cohen
    Chief Financial Officer




Exhibit 99.1



Intercure Informs That An Application To

Approve a Class Action Against 26 Cannabis

Companies in Israel, Including InterCure,

Was Filed to The Court In Israel


NEW YORK, TORONTO, and HERZLIYA, Israel — April 25, 2023 — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), the leading cannabis company outside of North America, announces that on April 23, 2023, it was informed that an application for approval of a class action in Israel was filed against twenty-six defendants, among them the leading cannabis groups in Israel, including the Company and three of its subsidiaries.


The subject of the application is the alleged claim that the defendants are in violation of the advertising prohibitions included in the Israeli regulations overseeing medical cannabis in Israel.


The Company is currently considering the application and its likelihood of acceptance.


About InterCure (dba Canndoc)


InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.


For more information, visit: http://www.intercure.co.




InterCure Ltd.

Amos Cohen, Chief Financial Officer